Appendix A. Acknowledgments

Reviewers

We gratefully acknowledge the following individuals who reviewed the initial draft of this report and provided us with constructive feedback. Acknowledgments are made with the explicit statement that this does not constitute endorsement of the report.

Technical Expert Panel

We wish to acknowledge the work of our technical expert panel:

Betty L. Chang, DNSc, FNP-C, FAAN
Professor, School of Nursing
University of California, Los Angeles
Los Angeles, CA

Seigward-Markus Elsas, MD
Clinical Fellow in Neurophysiology
University of California, Los Angeles
Los Angeles, CA

Glenn Clark, DDS
School of Dentistry
University of California, Los Angeles
Los Angeles, CA

Deborah Glik, Ph.D.
Associate Professor, School of Public Health
University of California, Los Angeles
Los Angeles, CA

Michael Goldstein, PhD
Professor, School of Public Health
University of California, Los Angeles
Los Angeles, CA

Eric Hurwitz, DC, PhD
Assistant Professor, Department of
Epidemiology,
School of Public Health, University of
California
Los Angeles, CA

Ka Kit Hui, MD, FACP
Director, UCLA Center for East-West
Medicine
University of California
Los Angeles, CA

Simon Mills, MA, MCPP, FNIMH
Director for the Center of Complementary
Medicine
University of Exeter
Exeter, England

Lakshmi C. Mishra, BIMS, M Pharm, PhD
Professor of Research
Southern California University of Health
Science
Whittier, CA

Shri K. Mishra, MD, MS, Doctor of
Ayurveda
Professor of Neurology and Coordinator
Integrative Medicine
USC School of Medicine
USC Keck School of Medicine
Los Angeles, CA

Lucy Postolov, LAc
Postolova Acupuncture Group
Los Angeles, CA

David Riley, MD
Clinical Associate Professor
University of North West Medical School,
Director, Integrative Medicine Research
Santa Fe, NM

Betsy B. Singh, PhD
Dean of Research
Southern California University of Health
Sciences
Whittier, CA

George Solomon, MD
Professor Emeritus, UCLA School of Medicine,
Dept. of Psychiatry and Biobehavioral Medicine
University of California
Los Angeles, CA

Hitoshi Tomizawa, MD
Director, Japanese Executive Medical Services,
Cedars-Sinai Medical Center
Los Angeles, CA

Xiao-Ping Xu, LAc
Burns and Allen Research Institute
Cedars Sinai Medical Center
Los Angeles CA

Appendix B. Search Methodologies

Coenzyme Q10 And Cancer Prevention/Treatment Search Methodology

SEARCH #1 (PERFORMED 11/16/01)

DATABASES SEARCHED/TIME PERIOD COVERED:

MEDLINE	1966-2001/Dec W2
MANTIS	1880-2001/Aug
Allied & Complementary Medicine	1984-2001/Dec
CancerLit	1975-2001/Oct
CAB HEALTH	1983-2001/Oct
TGG Health&Wellness DB	1976-2001/Nov W1
Biosis Previews	1969-2001/Nov W2
EMBASE	1974-2001/Nov W2
Social SciSearch	1972-2001/Nov W3
SciSearch Cited Ref Sci	1990-2001/Nov W3
SciSearch Cited Ref Sci	1974-1989/Dec
ELSEVIER BIOBASE	1994-2001/Nov W2

SEARCH STRATEGY:

ubiquinone OR ubidecarenone OR coenzyme q10 OR co-enzyme q10 OR coenzyme q 10 OR co-enzyme q 10 OR coenzyme q-10 OR co-enzyme q-10

AND

neoplasms(exploded) from Medline OR malignant neoplastic disease(exploded) from Embase OR cancer* in title or subject heading field from all other databases (exception – In CancerLit the terms for cancer were omitted and just the total of "coenzyme q-10" terms were used")

AND

Human

TOTAL NUMBER OF ITEMS RETRIEVED: 176

Vitamin C And Cancer Prevention/Treatment
Search Methodology

SEARCH #2a (PERFORMED 11/27/01)

DATABASES SEARCHED/TIME PERIOD COVERED:

MEDLINE	1966-2001/Dec W4
MANTIS	1880-2001/Aug
Allied & Complementary Medicine	1984-2001/Dec
CancerLit	1975-2001/Oct
CAB HEALTH	1983-2001/Oct
TGG Health&Wellness DB	1976-2001/Nov W2
Biosis Previews	1969-2001/Nov W3
EMBASE	1974-2001/Nov W3
Social SciSearch	1972-2001/Nov W4
SciSearch Cited Ref Sci	1990-2001/Nov W4
SciSearch Cited Ref Sci	1974-1989/Dec
ELSEVIER BIOBASE	1994-2001/Nov W4

SEARCH STRATEGY:

ascorbic acid(exploded)from Medline, Embase OR ascorbic acid from all other databases OR dehydroascorbic acid* OR ascorbate OR vitamin c OR antiscorbutic vitamin* OR cevitamic acid*

AND

neoplasms(exploded) from Medline OR malignant neoplastic disease(exploded) from Embase OR (cancer OR neoplasm*) in subject heading field from BIOSIS OR cancer* in title or subject heading field from all other databases OR neoplasm* from all other databases (exception – in CancerLit the terms for cancer were omitted and just the total of the "vitamin c" terms were used)

AND

(prevention OR preventive OR therapy OR therapeutic OR treatment) in title,subject heading fields

AND

human

TOTAL NUMBER OF ITEMS RETRIEVED: 1987

SEARCH #2b (PERFORMED 11/7/01)

DATABASES SEARCHED:
Cochrane Library

SEARCH STRATEGY:
vitamin c OR ascorbic acid OR ascorbate OR antiscorbutic vitamin OR cevitamic acid OR dehydroascorbic acid

AND

neoplasms(exploded)

TOTAL NUMBER OF ITEMS RETRIEVED:

The Cochrane Controlled Trials Register (CENTRAL/CCTR)
References - 92

Vitamin E And Cancer Prevention/Treatment Search Methodology

SEARCH #3a (PERFORMED 12/13/01)

DATABASES SEARCHED/TIME PERIOD COVERED:

MEDLINE	1966-2001/Jan W1
MANTIS	1880-2001/Oct
Allied & Complementary Medicine	1984-2001/Jan
CancerLit	1975-2001/Oct
CAB HEALTH	1983-2001/Oct
TGG Health&Wellness DB	1976-2001/Nov W4
Biosis Previews	1969-2001/Dec W2
EMBASE	1974-2001/Dec W2
Social SciSearch	1972-2001/Dec W3
SciSearch Cited Ref Sci	1990-2001/Dec W3
SciSearch Cited Ref Sci	1974-1989/Dec
ELSEVIER BIOBASE	1994-2001/Dec W2

SEARCH STRATEGY:

Vitamin e (exploded) from Medline OR vitamin e OR alpha tocopherol* OR D1 alpha tocopherol* OR d alpha tocopherol OR rrr alpha tocopherol* OR all rac alpha tocopherol*

AND

neoplasms(exploded) from Medline OR malignant neoplastic disease(exploded) from Embase OR (cancer OR neoplasm*) in subject heading field from BIOSIS OR cancer* in title or subject heading field from all other databases OR neoplasm* from all other databases (exception – in CancerLit the terms for cancer were omitted and just the total of the "vitamin e" terms were used)

AND

(prevention OR preventive OR therapy OR therapeutic OR treatment) in title,subject heading fields

AND

human

TOTAL NUMBER OF ITEMS RETRIEVED: 1990

SEARCH #3b (PERFORMED 12/19/01)

DATABASES SEARCHED/TIME PERIOD COVERED:
    Cochrane Library   1922-2001

SEARCH STRATEGY:
 vitamin-e

 AND

neoplasms (exploded) OR cancer*

TOTAL NUMBER OF ITEMS RETRIEVED:

        Database of Abstracts of Reviews of Effectiveness
        Abstracts of quality assessed systematic reviews: 1
        The Cochrane Controlled Trials Register (CENTRAL/CCTR)References: 112

Co Q10 Synonyms + Cancer
Search Methodology

SEARCH #4 (PERFORMED 1/18/02)

DATABASES SEARCHED/TIME PERIOD COVERED:

MEDLINE	1966-2002/JAN W3
MANTIS	1880-2001/Oct
Allied & Complementary Medicine	1984-2001/Feb
CancerLit	1975-2001/Oct
CAB HEALTH	1983-2001/Dec
TGG Health&Wellness DB	1976-2002/Dec W5
Biosis Previews	1969-2002/Jan W2
EMBASE	1974-2002/Jan W2
Social SciSearch(R)	1972-2002/Jan W3
SciSearch Cited Ref Sci	1990-2002/Jan W3
SciSearch Cited Ref Sci	1974-1989/Dec
ELSEVIER BIOBASE	1994-2002/Jan W2

SEARCH STRATEGY:

ubidecarenon? OR isoprostane? OR f2(2w)isoprostane?

AND

neoplasms(exploded) from Medline, Embase OR cancer* in title or subject heading field OR neoplasm* from all other databases (exception – in CancerLit the terms for cancer were omitted)

AND

human

TOTAL NUMBER OF ITEMS RETRIEVED: 127

Appendix C. Antioxidant Screener

Article#   **Antioxidant Screener**   **RAND EPC Alternative Medicine**   <u>Reviewers</u>:   <u>Assigned on</u>:

                                              _____   mm/dd/yy

                                              _____   mm/dd/yy

[article author, title, journal, date, vol, pages]

1. Data Source: **Circle One**
    - Article 1
    - Abstract of article 2
    - Conference proceeding................................ 3
    - Other (Specify_____) 4

2. What topic does the article study: **Check all that apply**
    - Vitamin C... π
    - Vitamin E... π
    - Co-Enzyme Q10.. π
    - Other (Specify_____) .. π (STOP)
    - Unclear... π

3. Condition(s) and/or disease(s) studied in article: **Check all that apply**
    - Cancer .... π
    - Cardiovascular Disease................................ π
    - No condition/disease................................... π (STOP)
    - Other (Specify_____) .... π (STOP)
    - Unclear... π

4. Subject Population: **Check all that apply**
    - Human... π
    - In vitro / In vivo .... π (STOP)
    - Animal .... π (STOP)
    - Other (Specify_____) .... π (STOP)
    - Unclear... π

5. Article Type: **Check all that apply**
    - Historical/Descriptive/System/Bkgrd .... π
    - Review/Meta-analysis................................... π
    - Pharmacological .... π
    - Clinical Study
        - Trial.. π
        - Cohort .... π
        - Other clinical study............................... π
    - Other (Specify_____) .... π
    - Unclear.. π

6. How is the intervention being used in the study?   **Circle One**
    - Treatment... 1
    - Primary prevention 2
    - Secondary prevention 3
    - Adjunct to conventional treatment................ 4
    - Other (Specify_____) .. 5
    - Unclear... 6

7. Language of Article: **Circle One**
    - English 1
    - Foreign 2

NOTES:

Abstract:

RAND EPC, CAM Project
Quality Review Form, Topic = ANTIOXIDANT

Article ID:_____   Reviewer:_____

First Author: _____
(Last Name Only)

Study Number: ___of____Description:_____
(Enter '1of 1' if only one)   (if more than one study)

1. Design: (circle one)
   RCT...1
   CCT...2
   Other.. ....3 **(STOP)**
   (If not RCT or CCT, change study design on cover sheet and STOP)

2. What topic(s) does the study report on?.........................(check all that apply)
   Vitamin C..❏
   Vitamin E..❏
   Co-Q10..❏
   None of the above...❏ **(STOP)**

2. What condition(s) does the study report on?   (circle one)
   Cardiovascular 1
   Cancer..2
   Both...3
   None...4 **(STOP)**

3. Is the study described as randomized?   (circle one)
   Yes 1
   No 2

4. If the study was randomized, was method of randomization appropriate?
                                                         (circle one)
   Yes 1
   No 2
   Method not described...8
   Not applicable 9

5. Is the study described as: (circle one)
   Double blind...1
   Single blind, patient 2
   Single blind, outcome assessment 3
   Open..4
   Blinding not described...8
   Not applicable 9

6. If reported, was the method of double blinding appropriate?
                                                         (circle one)
   Yes 1
   No 2
   Double blinding method not described...............8
   Not applicable 9

7. If study was randomized, did the method of randomization provide for concealment of allocation?   (circle one)
   Yes 1
   No 2
   Concealment not described.................................8
   Not applicable 9

8. Are withdrawals (W) and dropouts (D) described?   (circle one)
   Yes, reason described for **all** W and D 1
   Yes, reason described for **some** W and D 2
   Not described...8
   Not applicable 9

9. Is this a cross-over study design?   (circle one)
   Yes 1
   No 2
   Not described..8

10. Does the study population include a purposefully selected group of individuals chosen because they have any of the following characteristics?   (check all that apply)

Race:
    African-American ....❏ (01)
    Asian..❏ (02)
    Hispanic ....❏ (03)

Gender:
    Male...❏ (04)
    Female..❏ (05)

Age:
    Children (under 18)..❏ (06)
    Elderly (over 65)...❏ (07)

Miscellaneous:
    Smokers ....❏ (08)

Other:
    (Enter code: ____ ____, ____ ____, ____ ___, ____ ____, ____ ____)

None of the above ....❏ (97)

11. Does the study population include a purposefully selected group of individuals chosen because they have any of the following comorbidities?   (enter code or circle)

    Code: ____ ____, ____ ____, ____ ___, ____ ____, ____ ____

    Not applicable 99

12. Does the study population include a purposefully selected group of individuals chosen because they have any of the following predisposing factors?   (enter code or circle)

    Code: ____ ____, ____ ____, ____ ___, ____ ____, ____ ____

    Not applicable 99

13. If this study is from a larger trial, please note the name of original trial.
    (circle one or enter code)

ADMT...❏ (01)
ATBC..❏ (02)
CGPPP..❏ (03)
CHAOS...❏ (04)
GISSI/GIZZI...❏ (05)
HOPE..❏ (06)
MRC/BHF...❏ (07)
PHS II ....❏ (08)
SPACE..❏ (09)
SU.VI.MAX..❏ (10)
WHI ....❏ (11)
WHS ....❏ (12)

    Code: ____ ____

Not from a larger trial ....❏ (99)

Patient Characteristics – CARDIOVASCULAR

14.... What type of cardiovascular disease did the study report on? (check all that apply and/or add code)

    CAD ....π (01)
    CVA/TIA .... ρ (02)
    PVD ....ρ (03)
    CHF..ρ (04)
    Angina .... ρ (05)

                                Code: ____ ____

                                        ____ ____

                                        ____ ____

                                        ____ ____

    Not Applicable ....ρ (99)

15.... What was the severity of the disease?

                        Enter code: ____ _____
                        (enter 99 if not applicable)

Patient Characteristics – CANCER

16. What type of cancer did the study report on? (check all that apply and/or add code)

    Breast..ρ (01)
    Lung.. ρ (02)
    Prostate.. ρ (03)
    Oral...ρ (04)
    Cervix...ρ (05)
    Gastric .... ρ (06)
    Colon .... ρ (07)

                                Code: ____ ____

                                        ____ ____

                                        ____ ____

                                        ____ ____

    Not Applicable 99

17. What was the severity of the disease? (check all that apply and/or add code)
    Pre-cancerous...ρ (01)
    Localized.. ρ (02)
    Metastatic... ρ (03)

                        Other code: ____ ____

    Not Applicable   99

107

If the study has a control/usual care arm, enter that data in arm 1.
Otherwise, enter data for the groups in order of first mention.

Arm 1 of ___   Description:_____

19. What was the sample size in this arm?

18. What type of arm is this?   (circle one)

    Placebo 1
    Usual care 2
    Primary Antioxidant..3
    Other active treatment...4

___ ___ ___ , ___ ___ ___   ___ ___ ___ , ___ ___ ___
        Entering   Completing

(Enter 999,999 if not reported.)

20. Intervention:

Intervention	Daily Dose	Units		Route of administration	Duration	Units	
1 _____	_____	_____	taken	_____	_____	_____	
2 _____	_____	_____	taken	_____	_____	_____	
3 _____	_____	_____	taken	_____	_____	_____	
4 _____	_____	_____	taken	_____	_____	_____	
Enter code	Enter a number	1. μg		1. PO	Enter a number	1. Hour	8. Mean Year
		2. mg		2. IV		2. Day	9. Median Year
	998. ND	3. gm		8. ND	998. ND	3. Week	10. Maximum Month
	999. NA	4. IU		9. NA	999. NA	4. Month	11. Minimum Month
		8. ND				5. Year	12. Maximum Year
		9. NA				6. Mean Month	13. Minimum Year
						7. Median Month	98. ND
							99. NA

If the study has a control/usual care arm, enter that data in arm 1.
Otherwise, enter data for the groups in order of first mention.

Arm 2 of ___   Description:_____

19. What was the sample size in this arm?

18. What type of arm is this?   (circle one)

Placebo 1
Usual care 2
Primary Antioxidant...3
Other active treatment..4

___ ___ ___ , ___ ___ ___   ___ ___ ___ , ___ ___ ___
        Entering   Completing

(Enter 999,999 if not reported.)

---

20. Intervention:

Intervention	Daily Dose	Units		Route of administration	Duration	Units	
1 _____	_____	_____	taken	_____	_____	_____	
2 _____	_____	_____	taken	_____	_____	_____	
3 _____	_____	_____	taken	_____	_____	_____	
4 _____	_____	_____	taken	_____	_____	_____	
Enter code	Enter a number	1. μg		1. PO	Enter a number	1. Hour	8. Mean Year
		2. mg		2. IV		2. Day	9. Median Year
	998. ND	3. gm		8. ND	998. ND	3. Week	10. Maximum Month
	999. NA	4. IU		9. NA	999. NA	4. Month	11. Minimum Month
		8. ND				5. Year	12. Maximum Year
		9. NA				6. Mean Month	13. Minimum Year
						7. Median Month	98. ND
							99. NA

If the study has a control/usual care arm, enter that data in arm 1.
Otherwise, enter data for the groups in order of first mention.

Arm 3 of ___   Description:_____

18. What type of arm is this?   (circle one)

Placebo 1
Usual care 2
Primary Antioxidant..3
Other active treatment..4

19. What was the sample size in this arm?

___ ___ ___ , ___ ___ ___   ___ ___ ___ , ___ ___ ___
　　　　Entering　　　　　　　　　　　　Completing

(Enter 999,999 if not reported.)

20. Intervention:

Intervention	Daily Dose	Units		Route of administration	Duration	Units	
1 _____	_____	_____	taken	_____	_____	_____	
2 _____	_____	_____	taken	_____	_____	_____	
3 _____	_____	_____	taken	_____	_____	_____	
4 _____	_____	_____	taken	_____	_____	_____	
Enter code	Enter a number	1. µg		1. PO	Enter a number	1. Hour	8. Mean Year
		2. mg		2. IV		2. Day	9. Median Year
	998. ND	3. gm		8. ND	998. ND	3. Week	10. Maximum Month
	999. NA	4. IU		9. NA	999. NA	4. Month	11. Minimum Month
		8. ND				5. Year	12. Maximum Year
		9. NA				6. Mean Month	13. Minimum Year
						7. Median Month	98. ND
							99. NA

110

If the study has a control/usual care arm, enter that data in arm 1.
Otherwise, enter data for the groups in order of first mention.

Arm 4 of ___   Description:_____

18. What type of arm is this?   (circle one)
        Placebo 1
        Usual care 2
        Primary Antioxidant..3
        Other active treatment..4

19. What was the sample size in this arm?

___ ___ ___ , ___ ___ ___   ___ ___ ___ , ___ ___ ___
       Entering   Completing

(Enter 999,999 if not reported.)

20. Intervention:

Intervention	Daily Dose	Units		Route of administration	Duration	Units	
1 _____	_____	_____	taken	_____	_____	_____	
2 _____	_____	_____	taken	_____	_____	_____	
3 _____	_____	_____	taken	_____	_____	_____	
4 _____	_____	_____	taken	_____	_____	_____	
Enter code	Enter a number	1. µg		1. PO	Enter a number	1. Hour	8. Mean Year
		2. mg		2. IV		2. Day	9. Median Year
	998. ND	3. gm		8. ND	998. ND	3. Week	10. Maximum Month
	999. NA	4. IU		9. NA	999. NA	4. Month	11. Minimum Month
		8. ND				5. Year	12. Maximum Year
		9. NA				6. Mean Month	13. Minimum Year
						7. Median Month	98. ND
							99. NA

111

Outcomes

21. Type of outcomes measured:

Enter the code for each outcome measured.
_____ _____
_____ _____
_____ _____
_____ _____
_____ _____
_____ _____
_____ _____
_____ _____
_____ _____
_____ _____
_____ _____
_____ _____

Evaluation

22. When, relative to the start of the intervention, were outcomes reported?

Enter the number and letters in the appropriate box

	Number	**Unit**
1ˢᵗ follow-up		
2ⁿᵈ follow-up		
3ʳᵈ follow-up		
4ᵗʰ follow-up		
5ᵗʰ follow-up		
6ᵗʰ follow-up		
Additional follow-ups:		

Use the following abbreviations for units:

MI	minute
HR	hour
DY	day
WK	week
MO	month
YR	year
YRMN	mean for year
YRME	median for year
YRMX	maximum for year
YRMI	minimum for year
MOMN	mean for month
MOME	median for month
MOMX	maximum for month
MOMI	minimum for month
ND	not described
NA	not applicable

23. Is there a sub-group analysis?   (circle one)

Yes 1
No 2

If yes, code

_____ _____   _____ _____

_____ _____   _____ _____

_____ _____   _____ _____